Clinical Edge Journal Scan

Simulation shows impact of increased PSA testing on prostate cancer diagnosis


 


Key clinical point: Increased use of PSA testing and diagnostic activity increased the number of men diagnosed with low and intermediate-risk prostate cancer.

Major finding: The number of men diagnosed with prostate cancer increased by 48% in the high diagnostic activity model compared to the low diagnostic activity model (423 cases per 100,000 me per year vs. 286 cases per 100,000 men per year).

Study details: The data come from a cohort study of 188,884 men aged 64-77 years diagnosed with prostate cancer between 1996 and 2016 in Sweden. The researchers used a simulation model to compare scenarios of high and low diagnostic activity for prostate cancer.

Disclosures: The study was funded by the Swedish Cancer Society. The researchers had no financial conflicts to disclose.

Source: Bergengren O et al. JAMA Netw Open. 2021 May 17. doi: 10.1001/jamanetworkopen.2021.9444.

Recommended Reading

Cancer therapy affects sexual health in most patients
Federal Practitioner
The Effect of Radium-223 Therapy in Agent Orange-Related Prostate Carcinoma
Federal Practitioner
FDA approves first agent for PSMA-PET imaging in prostate cancer
Federal Practitioner
Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine
Federal Practitioner
Declines in PSA screening may account for rise in metastatic prostate cancers
Federal Practitioner
CCR score can guide treatment decisions after radiation in prostate cancer
Federal Practitioner
Healthy lifestyle may offset genetic risk in prostate cancer
Federal Practitioner
Abiraterone enhances progression-free survival in prostate cancer
Federal Practitioner
Serum metabolic profiling improves prostate cancer diagnosis
Federal Practitioner
PSMA therapy promotes similar prostate cancer survival regardless of regimen
Federal Practitioner